The first subtype encompasses mutations that consistently present in both primary gastric lesions and metastatic tumors, such as RHOA (6 mutations in primary gastric lesions/6 mutations in metastasis tumors) and TAF1L (1/1). This evidence concerns the gene TAF1L and metastatic neoplasm.